Brian Stamper Appointed Vice President, Cell Therapy Operations at Immunomic Therapeutics
Previous
Immunomic Therapeutics Appoints Vice President, Cell Therapy
Next
ITI Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma
